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hypertrophic cardiomyopathy’ by DDD pacing. Third, despite the
fact that the patients were mainly in New York Heart Association
functional class IV before DDD pacing, in both types of
cardiomyopathy a considerable increase in exercise capability is
achieved.h’ Moreover, in both conditions the beneficial effects of
chronic DDD pacing continue to be evident when pacing is
abruptly stopped.’" During 5 years’ follow-up a continuous
decrease in the size of the left ventricle was seen in dilated
cardiomyopathy.4 These important findings indicate that in both
types of cardiomyopathy DDD pacing in the long run seems to have
a beneficial impact on the damaged myocardium, which probably
undergoes secondary cellular/molecular changes in response to the
altered pattern of electrical activation.1.4
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Mitochondrial DNA mutations in the
myelodysplastic syndrome
SIR,-Rotig et all have reported the deletion of mitochondrial
DNA (mtDNA) in the haematopoietic tissue of a patient with
Pearson’s syndrome, a fatal bone marrow disorder with clinical
features similar to the myelodysplastic syndromes (MDS). This
prompted us to examine patients with primary MDS for mtDNA
mutations. The molecular analysis of mtDNA is usually difficult and
requires complex methodologies such as DNA sequencing. Thermal-
gradient-gel electrophoresis (TGGE)2,3 is a rapid alternative to screen
for base mutations in specific regions of mtDNA.
We extracted high molecular weight DNA from a marrow
aspirate taken from a 57-year-old white man at the time MDS was
diagnosed (refractory anaemia FAB subtype) and again 16 months
later when he presented with acute myeloid leukaemia (AML).
Standard sequence DNA was obtained from the peripheral blood of
a normal white man and in-vitro polymerase chain reaction testing
was done on all samples’ with primers spanning position 5’-14724
(heavy strand) to 15149-3’ (light strand) of human mtDNA. This
delineated PCR fragment encompassed some 498 bp of the
cytochrome b gene. PCR product cross-hybridisations was
followed by TGGE analysis of the products.!
We observed a single, polymorphic melting domain with respect
to the standard in the cytochrome b gene of mtDNA isolated at the
time of diagnosis of MDS. Heteroduplex fragment denaturation
began at 39&deg;C with complete strand separation at 52&deg;C. Repeat
TGGE 16 months later showed a second additional sequence
polymorphism in the cytochrome b gene with heteroduplex
denaturation starting at 37&deg;C and strand separation at 51&deg;C. The
calculated degree of difference between the patients’ samples with
respect to the standard6 indicated that mutation of the second
melting domain occurred as the patient progressed from MDS to
AML.
The importance of mtDNA mutations in the pathogenesis of
MDS cannot be assessed until more patients have been analysed.
However, the importance of normal mtDNA in haematopoiesis is
illustrated by the haematological abnormalities that result from
clonal deletions of mtDNA in the bone marrow (Pearson’s
syndrome)6 and the suppression of mitochondrial protein synthesis
by chloramphenicol. Similar haematological defects occur in
patients with MDS. This suggests a causal relation between the
clinical features of this disorder and mtDNA in bone marrow.
TGGE is a practical method to screen patients suspected of genetic
mutation in defined regions of the mitochondrial genome.
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Prognostic value of serum &bgr;2-microglobulin
in HIV infection
SIR,-Dr Lifson and colleagues (June 13, p 1436) describe the
importance of serum &bgr;2-microglobulin concentrations as predictors
of the progression to AIDS in people infected with HIV, indicating
that monitoring of &bgr;2-microglobulin might have therapeutic
implications. We evaluated &bgr;2-microglobulin in HIV-infected
intravenous drug users (IVDU) undergoing long-term treatment
with zidovudine.
&bgr;2-microglobulin (Latex immunoassay, normal range 12-25
mg/1) concentrations were measured in 36 HIV-infected patients
with stage II disease (CDC, Atlanta), treated with zidovudine 500
mg/day and 36 patients with AIDS receiving 750 mg/day.
&bgr;2-microglobulin was measured at 3, 6, 9, and 12 months of
treatment and compared with CD4 lymphocyte counts:
Months
0 3 6 9 12
-/77/<?/!77/’y7
m9/lJ*
HIV infectiont 2-7 (0-8) 2-3 (0-6) 2.5 (0-6) 2-7 (0-7) 2-7 (06)
AIDS 3-1 (1-0) 3-0(10) 2.8 (1-1) 3-0 (0-5) 3-1(03)
CD4 counts
f7/* *
HIV infection 204(174) 213(131) 258(213) 145(183) 192(170)
AIDS 98(129) 87(107) 98(198) 79(121) 111(165)
*Means (SD) shown, tincluding 4 patients with stage II disease who went
on to develop AIDS
In patients with stage II infection, &bgr;2-microglobulin dropped
significantly at 3 months and 6 months (p < 0’05); at the same time
CD4 counts rose significantly (p < 0-05). After 9 months of
treatment &bgr;2-microglobulin stabilised. A similar drop in
&bgr;2-microglobulin at 9 months (from 32 [0&deg;6] to 2-7 [0&deg;7] mg/l
p < 0-01) was seen in 4 of these patients who developed AIDS. CD4
counts in these 4 patients rose significantly up to 6 months, (from 64
[61] to 169 [l64]/fll at 6 months; p < 0-01).
In the patients with AIDS serum &bgr;2-microglobulin fell
significantly (p < 0,05) at 6 months, rising again at 9 months. CD4
counts were stable. 14 of the 36 patients died or had secondary
opportunistic diseases. In these 14, &bgr;2-microglobulin dropped from
3-5 (0-5) to 3-1 (1-6) (p < 0-05) at 6 months, with stable CD4 counts.
These results show that serum p2-microglobulin concentrations
fall in HIV-infected patients receiving zidovudine, as Lifson et a]
and others have reported.1-3 Concentrations fell progressively up to
6-9 months after start of treatment in both groups of patients,
whereas CD4 counts rose, during the same period, only in the
patients with CDC stage II disease. However, outlook with respect
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to survival for HIV-infected patients, as found by Jacobson et al,4
could not be judged from (32 microglobulin values since there were
no differences in concentrations between HIV-infected patients,
those who developed AIDS during the study, those who died, and
those who presented with secondary opportunistic diseases.
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SIR,-Evaluation of 214 HIV-1 seropositive homosexual men by
Dr Lifson and colleagues (June 13, p 1436) provides additional
evidence that measurement of &bgr;2-microglobulin adds information
to CD4 counts for estimating the risk of AIDS. This result accords
with and extends analyses of immune activation markers such as
&bgr;2-microglobulin and neopterin as predictors of AIDS.1-5
We extended our investigation of a cohort of 131 homosexual
men with incident HIV-1 infection to include various
immunological and virological markers.6 In addition to CD4
counts, p2-microglobulin, and p24 antigen, we evaluated serum
concentrations of interferon, neopterin, and p24 antibodies.
On the basis of measurements at various year points&mdash;eg, three
years after seroconversion-all markers apart from anti-p24 were
significant predictors of AIDS risk in univariate analyses.
Compared with the null Cox regression model, neopterin and
interferon concentrations were the best single predictors, followed
by &bgr;2-microglobulin concentrations and CD4 counts (figure).
Bivariate analyses revealed a similar picture, showing neopterin,
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interferon, and (32-microglobulin as significant joint predictors with
CD4%. Even more information was obtained by including the
three best markers neopterin, interferon, and CD4%. &bgr;2-
microglobulin was strongly correlated with neopterin, and seemed
to be a better predictor of AIDS later rather than earlier in the
course of disease (eg, five years after seroconversion). In addition,
the value of these markers may vary with the different
manifestations of AIDS, since interferon strongly predicted
opportunistic infections but not Kaposi’s sarcoma. 6
Our results generally accord with the conclusions of Lifson and
co-workers and contribute to the evidence that measurement of
serum soluble immune activation markers improves the prediction
of AIDS risk in individuals with HIV infection. Our data also
support the view that immune activation is involved in the
pathogenesis of AIDS.
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SIR,-Serum concentrations of &bgr;2-microglobulin are used
prognostically to monitor and predict progression of HIV infection
and, as Dr Lifson and colleagues report, they have a good
correlation with progression of the disease in homosexual and
bisexual men. Other published studies have evaluated its use as a
prognostic marker in that population, and in recipients of blood
products.l,2 However, there is some evidence that drug-injecting
behaviour can raise serum &bgr;2-microglobulin, and thus its prognostic
reliability in HIV-infected injecting drug users (IDUs) may be
affected. 3.4
We are conducting a prospective study to assess the prognostic
value of serum &bgr;2-microglobulin concentrations and other surrogate
markers in a cohort of 327 patients with HIV infection followed for a
mean of 4.7 months. Serum &bgr;2-microglobulin concentrations were
measured with a quantitative radioimmunoassay (Pharmada
Diagnostics, Uppsala, Sweden) at 3-6-month intervals. Statistical
analyses were done by means of the Statview II statistical package
(Abacus Concepts, Berkeley, California, USA). 226 patients were
drug users (69%), 52 were homosexual or bisexual men (16%), 45
were non-drug-user heterosexual men or women (14%), 3 were
recipients of blood products (0-9%), and 1 (0-3%) had unknown
risk factors for HIV infection. The table shows baseline serum
&bgr;2-microglobulin concentrations according to risk factor and Center
for Disease Control (CDC) staging. Serum &bgr;2-microglobulin
concentrations did not differ between the groups with respect to risk
factor for HIV infection, once CDC staging of the disease was taken
into account. Reliable information about their drug-injecting
behaviour could be assessed in 125 (55%) drug users. We classified
drug users as non-injecting (non-IDU) when history, clinical signs,
and urine toxicology analysis did not suggest injecting drug use for
at least one month before baseline &bgr;2-microglobulin measurement.
97 of 125 drug users (78%) were non-IDUs, whereas 28 (22%)
were IDUs. Mean serum &bgr;2-microglobulin concentrations at
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BASELINE SERUM &bgr;2-MICROGLOBULlN (mgjl)
CONCENTRATIONS IN 327 PATIENTS WITH HIV INFECTION*
..&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;
*Means(SDs) shown.&dagger;II vs III=0.038; !! vs IV p=0 001, III vs IV p=0 49 (not
*Means (SDs) shown. tll vs III p 03 II vs IV p=O vs IV p=Osignificant).&Dagger;II vs III p=0.008; II vs IV p=0.0008; III vs IV p=O 23 (NS). &sect; II vs III
p=074; II II vs IV p=004; III vs IV p<0’21.
baseline were 4-07 (SD 1-03) mg/1 for IDUs, 3-63 (1-08) mg/1 for
non-IDUs (p =0-058),3-63 (1-20) mg/1 for homosexual or bisexual
men (p=0-1l), and 3-35 (1-20) mg/1 for heterosexual patients
(p = 0-01) (p values are all for comparison with IDU group). The
groups did not differ according to CDC staging of HIV infection.
Additionally, serum &bgr;2-microglobulin concentration correlated
positively with the duration of drug addiction (r = 0-24, p = 0-02),
but no correlation was found between &bgr;2-microglobulin
concentration and time free of drug-injecting behaviour (r = 0-07,
p = 0-45). &bgr;2-microglobulin concentration was significantly and
negatively correlated with CD4 count (r = - 0-29, p==0 0011) for
both IDUs (r = - 0-41, p = 0-03) and non-IDUs (r = - 0-29,
p=0-0047). Furthermore, &bgr;2-microglobulin correlated positively
with other surrogate markers such as neopterin (r=0-71,
p=0-0001) and IgA (r=0-31, p=0.OO6).
&bgr;2-microglobulin is produced by stimulated lymphocytes, and
thus its serum concentration reflects the degree of immune-system
activation.5 Our results suggest that changes in &bgr;2-microglobulin in
HIV-infected drug users indicate differences in drug-injecting
behaviour. However, even in actively injecting drug users
&bgr;2-microglobulin concentrations are positively correlated with CD4
cell count, and this suggests that &bgr;2-microglobulin can also be a
useful prognostic marker in HIV-infected drug users. The positive
correlation with serum neopterin, a good prognostic marker in drug
users’ lends further support to its usefulness.
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TNF&agr; in stool as marker of intestinal
inflammation
SIR,-Dr Braegger et all suggested that tumour necrosis factor
alpha (TNF&agr;) concentrations in stool provide a simple way to
monitor disease activity in inflammatory bowel disease. They also
measured TNFex in stools of 14 children with acute diarrhoea, of
whom 3 had concentrations above the control range. They
suggested that stool TNFa may be raised in infectious colitis. We
have measured TNFA and interleukin-6 by ELI SA in stool filtrates
of children with acute diarrhoea2 (table).
Our study confims that in children with shigella diarrhoea,
TNFK concentrations are in the range reported for children with
TNF&agr; AND INTERLEUKIN-6 CONCENTRATIONS IN STOOL OF
CHILDREN
*No of cases with detectable cytokme (range or result)
tn=8.
N D = not detectable; threshold 10 pg/ml for TN Fa and 4 pg/ml for interleukin-6
inflammatory bowel disease. We hypothesise that local production
ofcytokines and other mediators of the inflammatory response may
mediate the local and generalised vasculitis that occurs in
shigellosis.3 These data confirm the suggestion that stool TNFxis is
raised in infectious colitis. In other infective conditions, serum
interleukin-6 is a better indicator of severity than TNF &agr;. 4,5 It would
be of interest to determine whether the same relation existed in
chronic inflammatory bowel disease.
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Tumour metastasis
SIR,-Dr Hart and Dr Saini (June 13, p 1453) review the biology
of tumour metastasis. We appreciate the difficulties inherent in
condensing such a complex subject to a form that is comprehensible
and interesting to the non-specialist, but there are two aspects that I
think cannot be over-emphasised. First, much of what is known
about the metastatic process (eg, figure 2) is only uncertain
hypothesis, having been deduced from models of invasion or
metastasis. Many of these models are of questionable validity;
certainly, extrapolation from such models to progression, invasion,
and metastasis in patients should be done with much caution. For
example, the suggestion that cadherins function as suppressors of
invasionl is based largely on measurements of the invasion by
tumour cells into fragments of embryonic chick heart or deposits of
collagen in tissue culture dishes.
Second, the discrimination between the metastatic and
tumorigenic phenotypes needs fuller consideration. We anticipate
that an event that reduces tumorigenicity will inevitably
compromise metastatic propensity, yet most studies of metastasis
pay scant attention to this connection. Thus, for example, the
conclusion that nm23 is a metastasis suppressor gene2 ignores the
